Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HIF-1 alpha gene therapy product: GZBX completed enrollment in a U.S. double-blind, placebo-controlled Phase I trial in 28 patients with critical limb ischemia

Genzyme Biosurgery (GZBX), Cambridge, Mass.
Product: HIF-1 alpha gene therapy

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE